A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase

Eisai Co., Ltd.142 enrolled

Overview

The purpose of this study is to confirm the efficacy of E2020 in patients with dementia with Lewy bodies (DLB).

This 52-week study consisted of 16-week randomized placebo-controlled (RCT, including 12-week Confirmatory Phase) and 36-week open-label extension phases. Of 142 DLB patients enrolled in the RCT phase (three arms: placebo, 5 mg, and 10 mg), 110 entered the extension phase. The placebo group of the RCT phase initiated active treatment at week 16, and the active groups maintained allocated treatment and dosages until week 24. After week 24, all patients received 10 mg. Dose reduction to 5 mg for safety concerns was allowed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

142

Conditions

Dementia With Lewy Bodies (DLB)

Interventions

Donepezil 5 mgDRUG

Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg

Donepezil 10 mgDRUG

Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg

Donepezil matched placeboDRUG

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria 1. Patients diagnosed as probable dementia with Lewy bodies (DLB) according to the consensus diagnostic criteria for DLB 2. Patients having caregivers throughout the study who submited written consent to cooperate with this study, who routinely stayed with patients 3 days or more a week (at least 4 hours a day), provided patients' information necessary for this study, assisted treatment compliance, and escorted the patients on required visits to study institution 3. Clinical Dementia Rating (CDR) score ≥ 0.5 4. Mini-Mental State Examination (MMSE) score of 10 to 26 Exclusion Criteria 1. Patients diagnosed with Parkinson's disease with dementia (PDD) 2. Patients who received anti-dementia drug therapy at the same institution 3. Patients who received anti-dementia drug therapy within 12 weeks before start of Screening 4. Patients with a complication of serious neuropsychiatric disease(s) such as stroke, brain tumor, schizophrenia, epilepsy, normal pressure hydrocephalus, mental retardation, brain trauma with unconsciousness, or a history of brain surgery causing unrecovered deficiency 5. Patients with severe extrapyramidal disorders (Hoehn and Hahr staging score ≥ IV) 6. Patients whose systolic blood pressure was less than 90 mmHg or pulse rate was less than 50 bpm at screening

Locations (56)

Outcomes

Primary Outcomes

Change From Baseline in Mini-Mental State Examination (MMSE) Score

The MMSE was used to measure cognitive impairment. The MMSE can evaluate overall cognitive function, and is widely used for the assessment of cognitive impairment in dementia patients. The questionnaire consists of 11 items, and each item aims to evaluate different cognitive domains such as orientation, memory, attention, and construction. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from baseline. Data are presented as change from baseline in mean MMSE +/- standard deviation.

Time frame: Week 12 for Confirmatory Phase

Change From Baseline in Neuropsychiatric Inventory (NPI-2) Score

The NPI was a questionnaire that quantified psychiatric symptoms and behavioral disorders in dementia. A total of 12 items (the original NPI-10 consisting of 10 behavioral domains: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor behavior, supplemented by 2 dementia with Lewy bodies (DLB)-relevant domains of sleep, and cognitive fluctuation \[reported as cognitive fluctuation inventory\]) were assessed. The score of each item was calculated as frequency (scale: 1=occasionally to 4=very frequently) x Severity (scale: 1=Mild to 3=Severe). The NPI-2 was calculated as the sum of the scores for hallucinations and cognitive fluctuation, to yield a possible total score of 0 to 24. Lower score=less severity. A negative change score from baseline indicated improvement. Data are presented as change from baseline in mean NPI-2 +/- standard deviation.

Time frame: Week 12 for Confirmatory Phase

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Anjo-shi, Aichi-ken, Japan

Unnamed facility

Nagoya, Aichi-ken, Japan

Unnamed facility

Toyokawa-shi, Aichi-ken, Japan

Unnamed facility

Chiba, Chiba, Japan

Unnamed facility

Fukui-shi, Fukui, Japan

Unnamed facility

Yoshida-gun, Fukui, Japan

Unnamed facility

Fukuoka, Fukuoka, Japan

Unnamed facility

Kitakyushu-shi, Fukuoka, Japan

Unnamed facility

Omuta-shi, Fukuoka, Japan

Unnamed facility

Gifu, Gifu, Japan

...and 46 more locations